Status:
COMPLETED
Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream
Lead Sponsor:
Medical University of Graz
Conditions:
Actinic Keratoses
Eligibility:
FEMALE
50+ years
Phase:
PHASE4
Brief Summary
Earliest Stage Treatment of Actinic Keratosis with Imiquimod 3.75% Cream: The study is to demonstrate that Aktinic Keratosis are present before they are clinically visible, i.e. in a subclinical stag...
Eligibility Criteria
Inclusion
- Inclusion
- Male and female supposed-healthy volunteer outpatients, age: \> 50 years.
- Diagnosis: patients with chronically UV-exposed photodamaged facial skin.
- Consent by signing the ICF (Informed Consent Form)
- Exclusion
- Current participation in another clinical trial
- Patients who are using topical glucocorticoids on the face.
- Known intolerance/hypersensitivity to imiquimod
- Pregnant/breastfeeding women
- Systemic disease, immunodeficiency
Exclusion
Key Trial Info
Start Date :
April 16 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 23 2021
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT04842422
Start Date
April 16 2021
End Date
August 23 2021
Last Update
January 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitätsklinik für Dermatologie und Venerologie
Graz, Austria, 8010